▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Jim Halley

TMFjimhalley

@jimhalley

Recent Articles by Jim Halley

Transferring a patient from the emergency area into the ICU

Oct 31, 2023 by Jim Halley

3 Green Flags and 1 Red Flag for Medical Properties Trust

The beleaguered healthcare REIT has made itself a less risky stock.

scientist altering DNA genome project

Oct 30, 2023 by Jim Halley

5 Reasons Beam Therapeutics Remains a Risky Stock

Shares of the gene-editing biotech might not have hit rock bottom yet.

Group of medical practitioners having a seminar in board room

Oct 28, 2023 by Jim Halley

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

The three companies are spending big on IBD therapies.

scientists high five smile

Oct 27, 2023 by Jim Halley

2 Green Flags and 1 Red Flag for Novartis Stock

The Swiss pharmaceutical company just posted strong Q3 numbers and is going through some big changes.

Scientists in a lab

Oct 26, 2023 by Jim Halley

3 Pharma Stocks That Are Screaming Buys in October

Each company delivers an above-average dividend and revenue growth.

sitting at dental chair dentist patient

Oct 25, 2023 by Jim Halley

3 Dental Supply Stocks You Can Sink Your Teeth Into

Long-term trends and margin improvements are driving growth for dental supply companies.

DNA genetic sequencing biotech (1)

Oct 23, 2023 by Jim Halley

3 Stocks Cathie Wood Is Buying That Should Be on Your List Too

The three companies are positioned to benefit from red-hot trends.

Jazz pharma

Oct 21, 2023 by Jim Halley

Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?

The venerable pharmaceutical companies' shares have slumped this year.

invitae

Oct 19, 2023 by Jim Halley

3 Things About Bristol Myers Squibb That Smart Investors Know

The stock is down this year, but will its struggles fade into the rearview mirror?

Scientists in a lab

Oct 19, 2023 by Jim Halley

4 Ways to Grow $100,000 Into $1 Million for Retirement

Investing for big-time growth doesn't have to be risky.

dnaphoto

Oct 19, 2023 by Jim Halley

3 Under-the-Radar Biotech Stocks to Buy in 2023

These three lesser-known biotech companies are profitable and growing revenue.

growgeneration

Oct 19, 2023 by Jim Halley

Which Is the Better Cannabis Growth Stock for You: Cresco Labs or TerrAscend?

Cannabis stocks are back in style, but is either one of these multi-state operators a long-term buy?

Physicians in a hospital operating room

Oct 14, 2023 by Jim Halley

2 Robinhood Stocks With Market-Beating Potential

These diamonds in the rough won't stay down.

pharmacy pharmacist drug medicine prescription (2)

Oct 13, 2023 by Jim Halley

Why Shares of Revolution Medicines Were Popping on Friday

The company released positive phase 1/1b trial data on two cancer therapies.

Senior patient looking through window at hospital

Oct 13, 2023 by Jim Halley

Why Shares of Harmony Bioscience Are Falling on Friday

The company reported underwhelming phase 3 trial results for Pitolisant to treat idiopathic hypersomnia.

using a stethoscope listen to the heartbeat of patient

Oct 13, 2023 by Jim Halley

Why Shares of T2 Biosystems Are Falling Friday

A revenue drop and a reverse stock split worried investors.

blood glucose monitor diabetes biotech

Oct 12, 2023 by Jim Halley

Why Shares of Insulet Dropped This Week

Positive news regarding diabetes therapy Ozempic worried investors.

guardant

Oct 12, 2023 by Jim Halley

Why Akero Therapeutics Shares Are Slumping This Week

Akero's lead therapy fell short of its goals in a phase 2b trial to treat NASH.

adaptimmune

Oct 12, 2023 by Jim Halley

Why Shares of ProKidney Were Dropping Thursday

Two factors led to the stock's slide on Thursday.

adaptimmune

Oct 11, 2023 by Jim Halley

Why Shares of Ardelyx Were Down Wednesday

The company's hopes for approval of a drug to treat chronic kidney disease took a hit.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services